Woo, XY, Giordano, J, Srivastava, A, Zhao, ZM, Lloyd, M, de Bruijn, R, Suh, YS, Patidar, R, Chen, L, Scherer, S, Bailey, M, Yang, CH, Cortes-Sanchez, E, Xi, Y, Wang, J, Wickramasinghe, JM, Kossenkov, AV, Rebecca, VW, Sun, H, Mashl, RJ, Davies, S, Jeon, R, Frech, C, Randjelovic, J, Rosains, J, Galimi, F, Bertotti, A, Lafferty, A, OFarrell, AC, Modave, E, Fang, B, Roth, JA, Meric-Bernstam, F, Davies, MA , Zheng, X, Zhang, X, Akcakanat, A, Yap, TA, Ha, MJ, Chen, H, Kopetz, S, Menter, DG, Westin, SN, Kim, M, Dai, B, Gibbons, DL, Tapia, C, Jensen, VB, Yennu Nanda, VG, Mlandsmo, GM Author Correction
Among the Eli Lilly trials is one for orforglipron (LY3502970), a novel, oral non-peptide GLP-1 RA, which is the subject of four trials in the clinicaltrials.gov data
& Selkoe, D
Novo Nordisk last month filed a petition to add semaglutide, the key ingredient in Ozempic and Wegovy, to an FDA list of drugs deemed too difficult to compound safely
The potential of Epitalon to extend telomeres and delay cellular aging is of particular interest
